Free Trial

Y-mAbs Therapeutics (YMAB) News Today

$12.22
-0.18 (-1.45%)
(As of 05/24/2024 04:00 PM ET)
Y-mAbs Therapeutics (NASDAQ:YMAB) Trading 3% Higher
Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Up 3%
Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Up 7.5%
Y-mAbs Therapeutics (NASDAQ:YMAB) Trading 7.5% Higher
Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target Raised to $22.00
HC Wainwright upped their target price on shares of Y-mAbs Therapeutics from $21.00 to $22.00 and gave the company a "buy" rating in a research report on Monday.
Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price Down 6.8%
Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Down 6.8%
Y-mAbs: There's A Ceiling Here Somewhere
Q1 2024 Y-mAbs Therapeutics Inc Earnings Call
Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Gap Down to $17.21
Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Gap Down to $17.21
43,700 Shares in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Bought by Sapient Capital LLC
Sapient Capital LLC purchased a new stake in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) during the 4th quarter, according to the company in its most recent filing with the SEC. The fund purchased 43,700 shares of the company's stock, valued at approximately $298,000. Sapient Ca
Y-mAbs Therapeutics (YMAB) Set to Announce Quarterly Earnings on Tuesday
Y-mAbs Therapeutics (NASDAQ:YMAB) will be releasing earnings after the market closes on Tuesday, May 7, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=590317)
Y-mAbs to Present at 2024 ASCO Annual Meeting
Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Up 7%
Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Up 7%
Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Up 4%
Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price Up 4%
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Recommendation of "Hold" by Analysts
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) has been given a consensus rating of "Hold" by the six ratings firms that are presently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating and four have assigned a buy rating to
Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Down 3.3%
Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Down 3.3%
Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Down 3.2%
Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Down 3.2%
Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Gap Down to $16.19
Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Gap Down to $16.19
Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price Up 5.9%
Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Up 5.9%
Denali Advisors LLC Sells 69,500 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)
Denali Advisors LLC lessened its holdings in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 80.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 16,400 shares of the company's stock after
Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Up 3.9%
Y-mAbs Therapeutics (NASDAQ:YMAB) Trading 3.9% Higher
Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price Up 4.3%
Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Up 4.3%
Y-mAbs Therapeutics Finance Chief Bo Kruse Resigns
Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Gap Down to $15.84
Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Gap Down to $15.84
Y-mAbs Therapeutics CFO Bo Kruse To Retire
GSA Capital Partners LLP Acquires 92,765 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)
GSA Capital Partners LLP lifted its holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 208.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 137,299 shares of th
Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price Down 8.3%
Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Down 8.3%
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Holdings Raised by Trexquant Investment LP
Trexquant Investment LP boosted its stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 417.5% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 76,585 shares of the company's stock
Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Up 8.2% Following Analyst Upgrade
Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Up 8.2% After Analyst Upgrade
Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target Raised to $26.00 at Canaccord Genuity Group
Canaccord Genuity Group increased their target price on Y-mAbs Therapeutics from $22.00 to $26.00 and gave the stock a "buy" rating in a report on Monday.
Q4 2023 Y-mAbs Therapeutics Inc Earnings Call
Y-mAbs Therapeutics (NASDAQ:YMAB) Sets New 1-Year High at $20.90
Y-mAbs Therapeutics (NASDAQ:YMAB) Hits New 52-Week High at $20.90
Get Y-mAbs Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter.

Tim Sykes’ Urgent Trade Alert: “Make this move now” (Ad)

WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…

Click here to see a unique election-year trade

YMAB Media Mentions By Week

YMAB Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

YMAB
News Sentiment

0.40

0.92

Average
Medical
News Sentiment

YMAB News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

YMAB Articles
This Week

7

2

YMAB Articles
Average Week

Get Y-mAbs Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:YMAB) was last updated on 5/28/2024 by MarketBeat.com Staff

From Our Partners